QUREuniQure N.V.
Price
+63%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growth steady, the market undecided.
We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our clinical candidates for the treatment of Huntington’s disease, refractory mesial temporal lobe epilepsy (“MTLE”), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 (“SOD1-ALS”).
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
uniQure N.V. (QURE) reported revenue of $3.6M in Q1 2026 (quarter ended Mar 31, 2026), up 127% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $54M. For the full year FY2025, revenue was $16M (−41% year on year) and net income −$199M. Its largest product in Q3 2025 (quarter ended Sep 30, 2025) was License at $3.6M, 97% of the disclosed total, well ahead of Collaborative at 3.2%. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as.Regulation FD disclosure · press release
- Jun 24, 2026On June 23, 2026, uniQure N.V. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 4,945,055 of the Company’s …Material agreement entered · Form 8-K
- Jun 22, 2026On June 19, 2026, the Company announced preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2025 · $3.7MThe company’s own SEC segment disclosure.
- License$3.6M97%
- Collaborative$119.0K3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.